Analysts expect that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will post earnings per share of $1.13 for the current quarter, Zacks reports. Three analysts have provided estimates for IDEXX Laboratories’ earnings, with the lowest EPS estimate coming in at $1.12 and the highest estimate coming in at $1.14. IDEXX Laboratories posted earnings of $1.05 per share during the same quarter last year, which would suggest a positive year over year growth rate of 7.6%. The firm is expected to issue its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that IDEXX Laboratories will report full-year earnings of $4.86 per share for the current fiscal year, with EPS estimates ranging from $4.84 to $4.88. For the next financial year, analysts forecast that the firm will report earnings of $5.57 per share, with EPS estimates ranging from $5.44 to $5.65. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $1.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. The business had revenue of $620.10 million for the quarter, compared to analyst estimates of $627.10 million. During the same quarter in the prior year, the company posted $1.23 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis.
Shares of IDEXX Laboratories stock traded down $7.32 during trading hours on Friday, hitting $272.56. The company’s stock had a trading volume of 12,751 shares, compared to its average volume of 419,812. IDEXX Laboratories has a twelve month low of $176.11 and a twelve month high of $292.17. The firm has a fifty day moving average of $279.53 and a 200-day moving average of $245.61. The stock has a market cap of $23.87 billion, a price-to-earnings ratio of 64.14 and a beta of 0.84. The company has a debt-to-equity ratio of 4.49, a quick ratio of 0.83 and a current ratio of 1.15.
In related news, Director Sophie V. Vandebroek sold 9,044 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $263.86, for a total transaction of $2,386,349.84. Following the transaction, the director now owns 12,116 shares of the company’s stock, valued at approximately $3,196,927.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Giovani Twigge sold 2,300 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $274.44, for a total value of $631,212.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,905 shares of company stock worth $20,052,806. 2.70% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bigelow Investment Advisors LLC raised its position in IDEXX Laboratories by 2.8% in the 2nd quarter. Bigelow Investment Advisors LLC now owns 1,363 shares of the company’s stock valued at $375,000 after purchasing an additional 37 shares in the last quarter. Captrust Financial Advisors grew its stake in IDEXX Laboratories by 32.5% during the 2nd quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock worth $42,000 after buying an additional 37 shares during the last quarter. Ropes Wealth Advisors LLC grew its stake in IDEXX Laboratories by 0.5% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 7,293 shares of the company’s stock worth $2,008,000 after buying an additional 38 shares during the last quarter. Nordea Investment Management AB grew its stake in IDEXX Laboratories by 0.9% during the 1st quarter. Nordea Investment Management AB now owns 4,485 shares of the company’s stock worth $1,003,000 after buying an additional 40 shares during the last quarter. Finally, Western Wealth Management LLC grew its stake in IDEXX Laboratories by 0.7% during the 2nd quarter. Western Wealth Management LLC now owns 5,669 shares of the company’s stock worth $1,562,000 after buying an additional 40 shares during the last quarter. 87.10% of the stock is currently owned by hedge funds and other institutional investors.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: What is Green Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.